UBS lowered the firm’s price target on Bristol Myers (BMY) to $52 from $54 and keeps a Neutral rating on the shares. Bristol Myers reported a strong beat and raise that was driven by foreign exchange and the legacy portfolio, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target raised to $56 from $54 at BofA
- Bristol Myers price target lowered to $53 from $62 at Wells Fargo
- Bristol-Myers Squibb: Hold Rating Amidst Strong Q1 Performance and Long-Term Growth Challenges
- Bristol Myers Squibb Q1 2025 Financial Results Overview
- Bristol-Myers Squibb’s Earnings Call: Strong Growth Amid Challenges